Vanguard Global Advisers
ABOS icon

Vanguard Global Advisers’s Acumen Pharmaceuticals ABOS Stock Holding History

Vanguard Global Advisers’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Hold
6,684
– – ﹤0.01% 3366
2026
Q1 		$15.8K Buy
+6,684
New +$17.1K ﹤0.01% 3385

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Vanguard Global Advisers's ABOS Position: Q2 2026 in Review

Vanguard Global Advisers held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 6,684 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3366.

Vanguard Global Advisers first reported a position in ABOS in Q1 2026 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Vanguard Global Advisers held 6,684 shares of Acumen Pharmaceuticals worth $17.8K as of Q2 2026.
  • Vanguard Global Advisers left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3366 holding.
  • Vanguard Global Advisers first reported a position in Acumen Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.